Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Alexandra J. Spencer, Paul F. McKay, Sandra Belij‐Rammerstorfer, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu, R. H. Shaw, Arabella Stuart, et al.
The Lancet (2021) Vol. 398, Iss. 10303, pp. 856-869
Open Access | Times Cited: 497
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 521-529
Open Access | Times Cited: 403
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 121-130
Open Access | Times Cited: 368
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
David Hillus, Tatjana Schwarz, Pinkus Tober‐Lau, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 11, pp. 1255-1265
Open Access | Times Cited: 339
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Tina Schmidt, Verena Klemis, David Schub, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1530-1535
Open Access | Times Cited: 319
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Bruno Pozzetto, Vincent Legros, Sophia Djebali, et al.
Nature (2021) Vol. 600, Iss. 7890, pp. 701-706
Open Access | Times Cited: 198
COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 158
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients
Roman Reindl‐Schwaighofer, Andreas Heinzel, Manuel Mayrdorfer, et al.
JAMA Internal Medicine (2021) Vol. 182, Iss. 2, pp. 165-165
Open Access | Times Cited: 118
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 10, pp. 951-963
Open Access | Times Cited: 116
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts
Ronak Rashedi, Noosha Samieefar, Niloofar Masoumi, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1294-1299
Open Access | Times Cited: 112
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
Nan-Chang Chiu, Hsin Chi, Yu‐Kang Tu, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 10, pp. 1211-1220
Open Access | Times Cited: 110
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
Cielo García‐Montero, Óscar Fraile-Martínez, Coral Bravo, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 433-433
Open Access | Times Cited: 104
Animal models for COVID-19: advances, gaps and perspectives
Changfa Fan, Yong Wu, Rui Xiong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 79
Quality by Design for enabling RNA platform production processes
Simon Daniel, Zoltán Kis, Cleo Kontoravdi, et al.
Trends in biotechnology (2022) Vol. 40, Iss. 10, pp. 1213-1228
Open Access | Times Cited: 73
Viral vector vaccines
Naina McCann, Daniel O’Connor, Teresa Lambe, et al.
Current Opinion in Immunology (2022) Vol. 77, pp. 102210-102210
Open Access | Times Cited: 70
Nanotechnology-based mRNA vaccines
Shuying Chen, Xiangang Huang, Yonger Xue, et al.
Nature Reviews Methods Primers (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 70
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate
Marcellus Korompis, Cynthia Voss, Shuailin Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Viral Vectors for COVID-19 Vaccine Development
Kenneth Lundström
Viruses (2021) Vol. 13, Iss. 2, pp. 317-317
Open Access | Times Cited: 85
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Annika Fendler, Lewis Au, Scott T.C. Shepherd, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1321-1337
Open Access | Times Cited: 82
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Gregory Milne, Thomas Hames, Chris J. Scotton, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1450-1466
Open Access | Times Cited: 78
A ‘mix and match’ approach to SARS-CoV-2 vaccination
Meagan E. Deming, Kirsten E. Lyke
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1510-1511
Closed Access | Times Cited: 66
COVID‐19: vaccination problems
Harald Brüssow
Environmental Microbiology (2021) Vol. 23, Iss. 6, pp. 2878-2890
Open Access | Times Cited: 61
Humoral immune response after different SARS-CoV-2 vaccination regimens
Ruben Rose, Franziska Neumann, Olaf Grobe, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top